Cargando…
Reslizumab in the management of poorly controlled asthma: the data so far
Interleukin-5, an important cytokine in the pathophysiology of asthma, participates in terminal maturation and increases chemotaxis, endothelial adhesion, and activation of eosinophils. Blockade of interleukin-5 activity with monoclonal antibodies have been successful in decreasing eosinophil counts...
Autores principales: | Maselli, Diego Jose, Velez, Maria Ines, Rogers, Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012840/ https://www.ncbi.nlm.nih.gov/pubmed/27621657 http://dx.doi.org/10.2147/JAA.S94164 |
Ejemplares similares
-
Role of biologics in severe eosinophilic asthma – focus on reslizumab
por: Pelaia, Girolamo, et al.
Publicado: (2016) -
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
por: Walsh, Garry M
Publicado: (2013) -
Reslizumab as add-on therapy in patients with refractory asthma
por: Virchow, J Christian, et al.
Publicado: (2020) -
Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
por: Pérez de Llano, Luis A, et al.
Publicado: (2022) -
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
por: Varricchi, Gilda, et al.
Publicado: (2017)